Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction (Q46697253)

24 December 2017

title

Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction (English)

1 reference

24 December 2017

0 references

1 reference

0 references

6

Weinshilboum RM

1 reference

24 December 2017

Lewis LD

1

1 reference

24 December 2017

Benin A

2

1 reference

24 December 2017

Szumlanski CL

3

1 reference

24 December 2017

Otterness DM

4

1 reference

24 December 2017

Lennard L

5

1 reference

24 December 2017

Nierenberg DW

7

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 October 1997

1 reference

24 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

24 December 2017

volume

62

1 reference

24 December 2017

issue

4

1 reference

24 December 2017

page(s)

464-475

1 reference

24 December 2017

Inflammatory bowel disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Human kidney thiopurine methyltransferase. Purification and biochemical properties.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Statistical estimations in enzyme kinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Computer Programmes for Processing Enzyme Kinetic Data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Intraindividual variability in red blood cell thiopurine methyltransferase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

Distribution of xanthine oxidoreductase activity in human tissues--a histochemical and biochemical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990125-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0009-9236(97)90125-9

1 reference

24 December 2017

PubMed ID

9357398

1 reference

24 December 2017